Indian pharma companies with exposure to GLP-1 receptor agonists and the weight loss medication market through CDMO, generics, or API supply.
Sectors represented: Healthcare
We identify and classify emerging risks through analysis of internal and external data, industry trends,. market study, regulatory requirements and expert insights. e potential impact on. the business. We identify and classify emerging risks through analysis of internal and external data, industry trends,. market study, regulatory requirements and expert insights.
Significant usage shifts and spending growth acceleration across geographies became apparent in 2023 and have contributed. to an increase in the outlook for medicine spending through 2028 of two percentage points to 5-8% CAGR, bringing global. spending on medicines at list prices to $2.3Tn. buted.
Statements. ®®. Lipaglyn and Bilypsa (Saroglitazar Mg). ®. The Company has been supplying the molecule in India over last several years under the brand names Lipaglyn and. ®. Bilypsa for multiple indications viz. ®®. Lipaglyn and Bilypsa (Saroglitazar Mg). ®. The Company has been supplying the molecule in India over last several years under the brand names Lipaglyn and. ®.
The approval and rapid uptake of GLP-1. agonist medicines for diabetes and obesity indications have. also contributed to shifting medicine use patterns. to reshape medicine spending. and usage patterns. The approval and rapid uptake of GLP-1. agonist medicines for diabetes and obesity indications have. also contributed to shifting medicine use patterns. Despite.
Diabetes: Anticipated to reach USD184 billion by 2028,. positioning it as the third-largest therapy area globally. Growth of 3–6% CAGR is supported by both established. treatments and newer GLP-1-based therapies. . Cardiovascular and Neurology: These segments are set g it as the third-largest therapy area globally. Growth of 3–6% CAGR is supported by both established.
Cardiovascular drugs. 1. 2022 saw a growing share of first-in-class medicines and. continued growth in number of specialty medicine launches. While the value and volume of the market grew, 2022 saw fewer. approvals of new drugs by the U.S. Food and Drug Administration. (USFDA). A total of 37 new drugs were approved in 2022,. compared to 50 in 2021. and volume of the market grew, 2022 saw fewer.
Company has historically been dominant, it continued to rank. among the top three players:. #1 in Anti-infectives (leader for over 15 years). #2 in Vitamins/Minerals/Nutrients (VMN). #3 in Gastrointestinal therapies. #3 in Pain and Analgesics continued to rank. among the top three players:. #1 in Anti-infectives (leader for over 15 years). #2 in Vitamins/Minerals/Nutrients (VMN).
In the US — net pharmaceutical spending rose by. 11.4% in 2024 to US $487 billion, driven mainly by a. narrow set of high-performing therapies. tailwinds. Therapeutic Breakthrough in Weight. Management. In the US — net pharmaceutical spending rose by. 11.4% in 2024 to US $487 billion, driven mainly by a. narrow set of high-performing therapies. Chief among.
Incorporated. our subsidiaries. in the US and. Singapore. 2015. How We. Evolved. Across. Decades. Paonta. Sahib facility. inspected by. the USFDA for. the first time. First Indian. Company. to launch. “Dydrogesterone”. Acquired brands of. Panacea Biotec Pharma. Limited enabling entry into. transplant and oncology. Acquired Daffy and. Combihale from Dr. A for. the first time. First Indian. Company.
During the upcoming 5-year period, a number of innovative. biologic products are anticipated to face loss of exclusivity. (LOE), paving the way for the introduction of biosimilars. ion. During the upcoming 5-year period, a number of innovative. biologic products are anticipated to face loss of exclusivity. (LOE), paving the way for the introduction of biosimilars. It is.
Pharmaceutical players building. complex generics and specialty. molecules portfolio. A defining shift is underway toward biologics, specialty. medicines, and personalized therapies, particularly in. oncology, immunology, and metabolic disorders such. as obesity. alty. molecules portfolio. A defining shift is underway toward biologics, specialty.